[ad_1]
Miami And PERTH, Australia, April 25, 2023 /PRNewswire/ — Bridgewest Group, recognized for building innovative companies in life sciences, software and deep technology, has formed the Lumacina business unit under Bridgewest Perth Pharma. Perth, Australia. The newly created business will utilize the proven team and manufacturing facility recently acquired by Bridgewest Group from Pfizer.Perth) Pt. Ltd., a subsidiary of Pfizer, Inc., and in addition to newly expanded capabilities, in particular, R & D. LumaCina markets sterile injectable drugs in international markets and is actively expanding its product portfolio under the LumaCina branding.
“Our recent acquisitions in Australia reflect our commitment to meeting the demand for high-quality pharmaceutical products both regionally and globally. Lumasina will increase our ability to help healthcare professionals find quality injectable drugs immediately when they need them,” said President Lumasina.
John Kaffer He was appointed president of Lumasina. He also serves as the Chief Commercial Officer of Bridgewest Perth Pharma Pty Ltd, a subsidiary of the Bridgewest Group. “Our recent acquisitions by Australia It is a reflection of the importance we place on meeting the growing demand for high quality pharmaceutical products both regionally and internationally. LumaCina enhances our ability to help healthcare professionals find quality sterile injectable drugs when they need them. Currently, 95% of our products are stored in the Australia/New Zealand But our growth in the region will soon change our reach, Kaffer says.
“We see our role in the industry as a value creator. We tap into our core entrepreneurial spirit while keeping our customers close. Jobs, increased product availability, new injectable drugs and great strength for a region poised to become a global leader.” Masood TaybiCo-Founder and CEO of Bridgewest Group.
Initially, Lumasina will market a select portfolio of pure injectable drugs to customers served by Pfizer before joining Bridgewest Group. Perth Utility. “We are in discussions with pharmaceutical companies discussing licensing opportunities to strengthen our portfolio. Our stellar regulatory history in multiple regulatory agencies in multiple countries allows us to bring products to market in areas where pharmaceutical manufacturers have not yet obtained approval, which adds significant value to many companies,” Kaffer said.
About LumaCina
Lumacina is a fully integrated global supplier of sterile injectables. Perth Australia. The team and facility have a 30-year history of manufacturing high-quality syringes with supply reliability and an exemplary regulatory record, most recently under Pfizer ownership (Perth) Pty Ltd Lumasina is investing in expanded capabilities including technology, equipment and R&D, with a strong pipeline in its portfolio of developing essential injectable drugs, high capacity, fill seal and multi-format vials. LumaCina is a portfolio company of the Bridgewest Group.
About the Bridgewest Group
Bridgewest Group is an innovative and privately held global investment firm. $3B In private capital. In the year Founded in 1999, the global organization has a long-standing reputation for creating and scaling transformative businesses to achieve greater success. Bridgewest Group leverages its expertise and global eco-community in key high-impact sectors including life sciences, software, semiconductors and artificial intelligence/deep tech. Customized financial investment services and diversified real estate holdings increase equity assets and support portfolio companies as they grow. Bridgewest Group is based in the US, with investments primarily in the US; Europe, Chinaand Australia.
US Media Contact: Jenny Bourbiel, [email protected]
Australian Media Contact: Ian Wisenberg, [email protected]
Source Bridgewest Group
[ad_2]
Source link
